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Monocytes are versatile cells that can
express different functional programs in
response to microenvironmental signals.
We show that primary blood monocytes
secrete the CXCL12 chemokine, and ex-
press the CXCR4 and CXCR7 receptors,
leading to an autocrine/paracrine loop
that contribute to shape monocyte differ-
entiation to a distinct type of macro-
phages, with an enhanced expression of
CD4, CD14, and CD163, or dendritic cells,
with a reduced functional ability to stimu-
late antigen-specific T-lymphocyte re-
sponses. The in vivo relevance of CXCL12
production by mononuclear phagocytes
was studied in metastatic melanoma tis-
sues by a thoroughly immunofluores-
cence phenotyping of CXCL12high ex-
pressing cells, which were CD45,
coexpressed the macrophage antigens
CD68, CD163, and CD209 and constituted
the 60%-90% of tumor-associated macro-
phages. Microarray analysis of primary
monocytes revealed that the vascular
endothelial growth factor and the angio-
genic chemokine CCL1 mRNA levels
were up-regulated in response to
CXCL12, leading to enhanced expres-
sion of both proteins. In addition, we
found that CXCL12 autocrine/paracrine
signaling down-regulates the expres-
sion of the transcription factor RUNX3
and contributes to maintain the long-
term CD4 and CD14 expression in mono-
cytes/macrophages. Together, these re-
sults suggest that autocrine CXCL12
production modulates differentiation of
monocytes toward a distinct program
with proangiogenic and immunosup-
pressive functions. (Blood. 2011;117(1):
88-97)
Introduction
Monocytes are not fully differentiated cells, derived from the bone
marrow, that circulate in blood during 1 to 3 days and enter
peripheral tissues to give rise to a heterogeneous lineage of
mononuclear phagocytes. Monocytes are highly recruited into foci
of active inflammation, but they also enter into healthy tissues as
part of the constitutive or steady-state trafficking to become
resident tissue macrophages.1 In response to inflammation or
microbial products, such as the pro-Th1 stimuli interferon- and
granulocyte macrophage colony-stimulating factor (GM-CSF) or
lipopolysaccharide (LPS), blood monocytes differentiate to inflam-
matory macrophages (M1) and dendritic cells (DCs). In contrast, in
response to pro-Th2/anti-inflammatory stimuli (interleukin-4 [IL-
4], IL-10 and M-CSF) monocytes become anti-inflammatory
macrophages (M2).2 In vitro, human monocytes can differentiate
into DCs in response to GM-CSF and IL-4 or into GM-CSF–
derived macrophages (M1), or M-CSF–driven macrophages (M2).
In the tumor microenvironment, incoming monocytes are influ-
enced by tumor-derived growth factors, especially M-CSF, IL-10,
IL-6, and transforming growth factor- (TGF-), which switch
monocyte differentiation toward M2 macrophages rather than M1
or DCs.3,4 Thus, monocytes are versatile cells that can express
different functional programs in response to environmental signals.
Blood monocytes are recruited into tissues in response to
chemoattractants, most of which belong to the chemokine family.5
Chemokines are small (8-14 kDa) secreted proteins that regulate
cell trafficking through interactions with a subset of 7—transmem-
brane, G-protein coupled receptors. The chemokine CXCL12
(stromal cell-derived factor-1, SDF-1) plays a critical role in
monocyte extravasation and is both expressed under homeostatic
conditions at sites where resident macrophages are present, and
highly inducible in some pathologic conditions involving ischemia
and/or hypoxia and in proangiogenic environments, such as
tumors.6 CXCL12 is expressed by stromal cells in several tissues
and organs, including skin, thymus, lymph nodes, lung, liver, and
bone marrow. Monocytes express at the plasma membrane the
2 cognate receptors for CXCL12, CXCR4, and CXCR7.7 Binding
of CXCL12 to CXCR4 activates multiple downstream pathways
that mediate the migration and survival of lymphocytes and
monocytes and that regulate gene expression through activation of
nuclear factor B,8 Erk/ELK pathway,9 AP-110 and JAK/STAT
activation.11 Functional levels of CXCR4 in monocytes are tran-
siently elevated at the beginning of differentiation, followed by
down-regulation in macrophages.12 Recent works indicate that
CXCR7 signals through -arrestin in the absence of G protein
activation or by its ability to alter CXCR4-mediated signaling
through receptor heterodimerization.13,14
Microenvironmental signals, which operate through the con-
trol of gene expression by transcription factors, dictate the
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terminal differentiation process of monocytes. The RUNX family
of context-dependent transcriptional regulators controls prolifera-
tion, hematopoiesis, neurogenesis, and lineage-specific gene expres-
sion in major developmental pathways.15,16 In the myeloid lineage,
RUNX3 mediates TGF- signaling in DCs and is essential for the
generation of Langerhans cells.17 Thus, the transcriptional factor
RUNX3 is a good candidate for regulating monocyte differentiation.
The role of chemokine CXCL12 in the immune system has been
focused in the ability to orchestrate directional migration to
selected tissues of a wide spectrum of cells. However, less is known
on the transcriptional events elicited in response to this chemokine.
In this work, we have investigated the effect of CXCL12 on
monocyte differentiation. Our data indicate that CXCL12, by an
autocrine/paracrine mechanism, regulates a distinct program of
macrophage differentiation, characterized by the expression of the
angiogenic factors vascular endothelial growth factor (VEGF) and
CCL1. Interestingly, we found CD163CD209CXCR4 macro-
phages at tumoral perivascular sites, which also highly expressed
CXCL12. As a part of the transcriptional program induced by
CXCL12, we show the down-regulation of RUNX3 expression,
which maintains CD4 and CD14 expression in mononuclear
phagocytes.
Methods
Cells and transfections
Hospital General Universitario Gregorio Maran˜o´n (HGUGM) Ethical
Committee approved experimentation involving human cells. Peripheral
blood mononuclear cells were obtained from healthy donors by Ficoll
density gradient centrifugation. Monocytes were isolated with anti-
CD14–labeled magnetic microbeads or monocyte isolation kit (Miltenyi
Biotec) obtaining an enrichment of 99% and 95%, respectively. Primary
cells, monocytic THP-1, and U-937, and lymphoid HSB-2 cell lines were
cultured in Teflon dishes in RPMI 10% fetal calf serum (FCS). Mono-
cyte-DC in vitro differentiation was induced with GM-CSF (1000 U/mL)
plus IL-4 (1000 U/mL; R&D Systems) and maturation with LPS from
Escherichia coli 055:B5 (10 ng/mL; Sigma-Aldrich). Monocytes were
differentiated to macrophages with M-CSF (10 ng/mL). THP-1 cells were
transfected with 2 g of small interfering RNA (siRNA) by using diluted
X-treme reagent (Roche Applied Science). The silencing efficiency was
checked by flow cytometry or Western blot within 24-48 hours, and
THP-1 siRNA transfectants were assayed 48 hours posttransfection.
Reagents, antibodies, and siRNAs
The chemokine CXCL12 was from R&D Systems. The CXCR7 antag-
onist CCX733 was kindly provided by Dr Penfold (Chemocentryx). The
CXCR4 antagonist AMD3100 was from Sigma-Aldrich. Antibodies were
as follows: RUNX3 (Alexis Biochemicals); GAPDH, FITC-CD163 (Santa
Cruz Biotechnology); anti–human melanoma HMB-45 and Factor
VIII (DakoCytomation); Tie-2 (Biolegend); FITC-CD14, percP-CD1a,
PercP-HLA-DR (anti–MHC-II), PE-CD80, PE-CD83, PE-CD86, FITC-
CD209, PE-CXCR4 clone 12G5, and FITC-CD90 (Becton Dickinson);
CXCR4 clone 44 717, CXCR4 clone 12G5, CXCR7-PE clone 11G8, and
goat anti–human CXCL12 were form R&D Systems; CXCR7 antibody
clone 11G8 (Chemocentryx); VE-Cadherin was kindly provided by Dr
Sa´nchez-Madrid (Hospital de la Princesa, Madrid, Spain); rabbit anti–
human CXCL12, biotinylated anti–human CXCL12, rabbit anti–human
M-CSF, biotinylated anti–human M-CSF (Peprotech). Fluorochrome-
conjugated antibodies were from Jackson ImmunoResearch Laboratories.
RUNX3 siRNA (ID no. 107390 and ID no. 115509), CXCR7 siRNA
(ID no. 109229), and negative control siRNA (AM4611) were from Ambion.
Cell migration
Freshly isolated monocytes (1  105 cells) were pretreated or not with
CXCR4 (AMD3100; 25 g/mL) or with CXCR7 (CCX733; 100nM)
antagonists for 3 hours or with anti-CXCR4 and/or anti-CXCR7 mono-
clonal antibody (mAb) at 50 g/mL for 1 hour in RPMI at 37°C to
block recycling receptors. Monocytes were allowed to migrate to
CXCL12 (100 ng/mL) for 1 hour and quantified as previously described.18
Silencing of CXCR7 was performed in THP-1 cells, and the effect
on CXCL12 migration was evaluated within the 48 hours after transfec-
tion. Relative migration to CXCL12 was represented. Assays were run
in duplicate.
Antigen-specific T-lymphocyte proliferation assay
Monocytes were derived to DCs, in the absence or presence of CXCL12
(100 ng/mL). At day 6, purified protein derivative (PPD; 50 IU/mL),
tetanus toxoid (TT; 10 fl/mL), or no antigen were added, and 4 hours later,
cells were treated with LPS (10 ng/mL) for 1 more day to obtain mature
DCs. Autologous T lymphocytes were purified (Pan-T cell isolation kit;
Miltenyi Biotec) and labeled with carboxyfluorescein succinimidyl ester
(CFSE). Pulsed mature DCs were washed, counted, and adjusted at ratios of
1:10 DC/T cells in 300-L final volumes of medium (RPMI 1640 sup-
plemented with 10% autologous serum). Assays were performed in
triplicates. After 6 days of coculture, lymphocyte proliferation was assessed
by the CFSE-dilution method.
Microarrays
CD14 monocytes (2.5  106 cells) isolated from 3 different blood donors
were cultured in Teflon dishes for 1 hour in RPMI 10% FCS and then, were
treated or not with CXCL12 for 6 hours. Total RNA from each condition
was extracted and purified using the RNeasy kit (QIAGEN). Labeled RNA
was used as hybridization probes on human Codelink Whole Genome
Bioarray. All experimental procedures were performed following manufac-
turer instructions. Microarrays were scanned with a GenePix 4000B (Axon
Instruments) scanner. Scanned images and raw data were processed using
the Codelink Expression Software. Log2-transformed intensity values were
used for gene expression analysis. The ratio of Log2 intensity data
corresponding to untreated monocytes versus CXCL12 stimulated mono-
cytes was calculated for each single blood donor (n  3). All microarray
data have been deposited into the Gene Expression Omnibus (GEO)
database under accession number is GSE24496.
Real-time PCR and qualitative PCR
Total RNA from 2.5  105 cells was extracted with the RNasey kit. Total
RNA and cDNAs were quantified with nanodrop (Thermo Fisher Scien-
tific). The GeneAmp Gold RNA was performed using Lightcycler FastStart
DNA Master plus SYBR Green I kit in a Capillar Lightcycler (Roche).
The reactions were carried out following the manufacturer instructions. The
DNA Master SYBR Green I mix contained 4mM MgCl2. For RUNX3
amplification, annealing temperatures at 56°C were used. The specificity of
the polymerase chain reaction (PCR) product was determined by melting
curve analysis and by agarose gel eletrophoresis. Specific primers were
used for RUNX3 forward primer 5-TCGGAACTGAACCCATTCTC-3
and reverse 5-GCCAGAGGATGTCCGTAGT-3; GAPDH forward primer
5-GAGTCAACGGATTTGGTCGT-3 and reverse 5-GGTGCTAAG-
CAGTTGGTGGT-3 as control. Oligonucleotides for CCL1 were designed
according to the Roche software for qualitative PCR (qPCR), and RNA was
amplified using the Universal Human Probe library (Roche). Conventional
RUNX3 PCRs were performed using GC-rich PCR System (Roche), and
gel was stained with SYBR Gold (Molecular Probes). Results were
normalized according to the expression levels of 18S and GAPDH RNA.
ELISA and flow cytometry
Supernatants from 48 hours cultured cells (1  106 cells) were collected
and frozen. Human VEGF enzyme-linked immunosorbent assay (ELISA)
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kit, anti–human CXCL12, and anti–human M-CSF antibodies for capture
and detection were from Peprotech. Human IL-10 ELISA kit was from
Immunotools. The assays were performed following manufacturer instruc-
tions. Samples were run in triplicate.
Direct staining of blood samples with anti–CXCR7-PE or anti–CXCR4-PE,
was followed by Facs lysis solution (BD). Detection of membrane CXCR4 and
CXCR7 receptors were performed incubating cells for 15 minutes
at 4°C with the appropriate antibodies diluted in phosphate-buffered saline
with 2% FCS, 0.01% NaN3. Simultaneous permeabilization and fixation
was performed with 1.85% formaldehyde 0.2% Triton X-100 in phosphate-
buffered saline for 15 minutes. Intracellular CXCL12 and CCL1 were
detected by flow cytometric analysis using Cytofix/Cytoperm kit (BD).
For RUNX3 intracellular staining cells were fixed with 2% formaldehyde
for 10 minutes at 37°C, and permeabilized with ice-cold 90% methanol for
30 minutes at 4°C and frozen. Cells were analyzed on a FACScan cytometer
using CellQuest software (BD).
Confocal microscopy and immunohistochemistry
HGUGM Ethical Committee approved the protocols and process involving
melanoma samples. Melanoma metastases were immediately frozen, and
acetone-fixed 4-m–thick sections were first incubated with 10% nonim-
mune goat serum (Zymed). Samples were then incubated for 1 hour at
23°C with the appropriated antibodies or isotype-matched control antibod-
ies. All antibodies were first tested for reactivity on lymphoid tissue. The
slides were mounted using an aqueous permanent mounting medium
(DAKO). Confocal microscopy images were captured using a Leica
SP2-AOBS confocal microscope.
Western blot
Cells (2.5  106) were washed and then lysated in sodium dodecyl sulfate
(SDS) polyacrylamide gel electrophoresis buffer (100mM Tris-HCl,
pH 6.8, 0.05mM sodium orthovanadate, 1mM EDTA [ethylenediaminetet-
raacetic acid], 3% SDS, 25mM dithiothreitol, 5% glycerol). Proteins were
resolved by SDS polyacrylamide gel electrophoresis and transferred to
polyvinylidene fluoride membranes that were subsequentially incubated
with 0.2 g/mL anti-Runx3 antibody and horseradish peroxidase-
conjugated secondary antibodies. Immunoreactive bands were visualized
using enhanced chemiluminescence reagents.
Statistical analysis
Results are given as means 	 standard deviation (SD), and statistical
significance was determined. The Wilcoxon test was used for nonparamet-
ric data analysis. When normal distribution of data were assessed with the
Kolmogorov-Smirnov test, means of 2 groups were compared with the
Student paired t test. Statistical significance was determined as P values of

 .05. SPSS 15.0 software was used for statistical analyses.
Results
CXCR4 and CXCR7 are expressed by blood monocytes and
both are necessary for CXCL12-mediated chemotaxis
The chemokine CXCL12 has 2 known receptors, the initially
described CXCR4 and the second cognate receptor CXCR7.7
CXCL12-CXCR4 interaction mediates migration of peripheral
blood monocytes (PBMos), but the role of CXCR7 in monocyte
chemotaxis is yet unexplored. Controversial results and hypothesis
have been proposed for CXCR7 function in different migration
models and cell types.19,20 Recent works indicate that the role of
CXCR7 in cell migration is variable and depends on the particular
cell system.21,22 We first analyzed the surface expression of CXCR4
and CXCR7 in whole blood samples by flow cytometry. Compared
with the high CXCR4-expression of PBMos, CXCR7-surface
expression showed high interindividual variability among blood
donors, ranging from high to low (Figure 1A and data not shown).
However, a significant level of total CXCR7 was detected after
monocyte permeabilization (Figure 1A). In primary lymphocytes
and the THP-1 (monocytic) and HSB-2 (lymphoid) cell lines,
which were included for comparison, CXCR7 was marginally
expressed at the cell surface and mainly detected in a large
intracellular pool (Figure 1A and supplemental Figure 1A, avail-
able on the Blood Web site; see the Supplemental Materials link at
the top of the online article). We next assessed the effect of receptor
blocking with specific mAbs, as well as with receptor antagonists,
AMD310023 for CXCR4 and CCX73320 for CXCR7, in the
Figure 1. Expression of CXCL12 receptors, CXCR4 and CXCR7, in blood monocytes and contribution to CXCL12 mediated-chemotaxis. (A) CXCR4 and CXCR7
immunofluorescence of blood monocytes from 2 different donors (top and middle panels), and the THP-1 monocytic cell line (bottom panel). Unpermeabilized (membrane, left
and middle) and permeabilized (total, right) cells were analyzed by flow cytometry. (B) Monocytes were pretreated with the CXCR4 antagonist (AMD3100; 25 g/mL), with the
CXCR7 antagonist (CCX733; 100nM) or with anti-CXCR4/CXCR7 antibodies (50 g/mL) and allowed to migrate to CXCL12. Untreated () cells were used as migration control
(100%). CXCL12-induced chemotaxis of CXCR7 siRNA-transfected THP-1 cells was compared with control siRNA-transfected cells. The percentages of migration referred to
CXCL12-mediated chemotaxis are shown. Mean 	 SD; n  3; *P 
 .05, **P 
 .005, ***P 
 .0005.
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CXCL12-mediated chemotaxis of blood monocytes (Figure
1B). Either the CXCR4 or the CXCR7-blocking mAbs inhibited
CXCL12-triggered PBMo chemotaxis by approximately
50%, whereas a combination of both blocking mAbs almost
completely abrogated the chemotactic response. In addition, either
AMD3100 or CCX733, significantly reduced the CXCL12-induced
migratory response, whereas they did not affect cell viability at the
doses used (Figure 1B and supplemental Figure 1B). The involve-
ment of CXCR7 in CXCL12-mediated chemotaxis was further
analyzed using CXCR7 depletion by siRNA in THP-1 cells
(supplemental Figure 1C), which reduced the migratory response
compared with control siRNA cells (Figure 1B). Thus, both
CXCR4 and CXCR7 receptors are expressed by primary mono-
cytes and contribute to CXCL12-mediated chemotaxis.
CXCL12 is constitutively expressed and secreted by
monocytes and modifies macrophage differentiation
Next, we analyzed by flow cytometry the CXCL12 expression in
freshly isolated monocytes and lymphocytes, as well as in both
THP-1 and HSB-2 cell lines. In all cases, we detected a large
constitutive intracellular pool of CXCL12 (Figure 2A). Further-
more, monocytes (primary, THP-1, and U-937 cells) and lympho-
cytes (primary and HSB-2 cells) secreted significant amounts of
this chemokine to the medium during 48 hours of culture, which
was comparable with the amount of CXCL12 secreted by tumor-
associated fibroblasts24 (Figure 2B). These results indicate that
CXCL12 secretion could serve both to paracrine and autocrine
functions in monocytes. CXCL12 ligand binding is known to
Figure 2. Intracellular expression and secretion of CXCL12 and its role in monocyte to macrophage differentiation. (A) Intracellular expression of CXCL12 in
monocytes (primary or THP-1 cell line) or lymphocytes (resting or HSB-2 T cell line) detected by flow cytometry in permeabilized cells. Control isotype (filled histogram) and
CXCL12 (empty histogram) are shown in a representative experiment of 3. (B) ELISA quantification of the secreted CXCL12 during 48 hours of culture by peripheral blood
monocytes, monocytic cell lines (THP-1 and U-937), and lymphocytes (resting and HSB-2). Mean 	 SD; n  3. (C) CD163 membrane expression on peripheral blood
monocytes treated for 48 hours with CXCL12 (100 ng/mL), CXCR4 antagonist (AMD3100; 25 g/mL), CXCR7 antagonist (CCX733; 100nM) or untreated () was analyzed by
flow cytometry. Mean fluorescence intensity (MFI) of positive cells was determined and fold change regulation relative to untreated control cells is represented. Mean 	 SD;
n  4. (D) M-CSF ELISA quantification of culture supernatants of peripheral blood monocytes treated with AMD3100 and/or CCX733 at the concentrations previously indicated
during 48 hours. Mean 	 standard error; n  3; *P 
 .05. (E) CD14, CD4, and CD163 expression analysis by flow cytometry of M-CSF–derived macrophages (5 days) in the
absence (control, shaded profile) or in the presence of CXCL12 (100 ng/mL, black line). A representative experiment of 3 is shown.
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induce CXCR7 receptor internalization,21 a feature that is consis-
tent with the observed intracellular pool of CXCR7. The above
observations led us to hypothesize that the CXCL12 autocrine loop
might contribute to the spontaneous differentiation of monocytes
toward macrophages that occurs upon in vitro culture, even in the
absence of exogenous M-CSF. Therefore, we assessed the effect of
CXCR4 and CXCR7 receptor antagonists on the expression of the
macrophage scavenger receptor CD163 (Figure 2C). Either
AMD3100 or CCX733 significantly reduced CD163 expression of
monocytes after 48 hours of culture, suggesting that autocrine
CXCL12 production may play a role in the default macrophage
differentiation pathway. As M-CSF is a major macrophage differen-
tiation factor, we measured its baseline production under the same
experimental conditions or in the presence of exogenous CXCL12
at 100 ng/mL (equivalent to 12.5nM). Figure 2D shows that the
autocrine production of M-CSF was significantly increased by
exogenous CXCL12, whereas a combination of CXCR4 and
CXCR7 receptor antagonists partially blocked this response,
suggesting that CXCL12 may induce the differentiation of human
monocytes, at least partially, through the regulation of autocrine
M-CSF production. Interestingly, addition of exogenous CXCL12
during in vitro M-CSF–induced macrophage differentiation commit-
ted a particular macrophage phenotype characterized by higher
surface expression of CD4, CD14, and CD163 compared with
M-CSF alone, suggesting that CXCL12 might impinge a specific
pathway of macrophage differentiation (Figure 2E).
Differentiation of monocytes to DCs in the presence of CXCL12
decreases the functional ability of DCs to stimulate
T-lymphocyte responses
To test the hypothesis that CXCL12 signaling might also modulate
monocyte differentiation to DC, PBMos were derived to DCs with
GM-CSF and IL-4, in the presence or absence of CXCL12
(CXCL12-DCs and c-DCs, respectively). Monocyte-derived DCs
in the presence of CXCL12 displayed delayed down-regulation of
CD14 and delayed up-regulation of CD1a at early DC differentia-
tion compared with c-DCs (day 3; Figure 3A; n  5). However,
those differences disappeared during the differentiation process,
and both fully differentiated CXCL12-DCs and c-DCs showed
similar expression of CD1a, CD209, and MHC-II (immature
DCs day 6), and had similar maturation, displaying high expression
of CD80, CD83, and CD86 (Figure 3B and supplemental Figure
2; LPS-matured DCs day 8; n  10). We also analyzed the capacity
of c-DCs and CXCL12-DCs to present specific antigens to
autologous T lymphocytes. As shown in Figure 3C, CXCL12-DCs
had reduced ability to stimulate antigen-specific T-cell proliferation
compared with c-DCs, which ranged from approximately 50% inhi-
bition of the PPD response and approximately 25% of TT response.
These results suggest that CXCL12 may modulate the ability of
DCs to induce antigen-specific T-cell responses. Therefore, despite
similar up-regulation of antigen-presenting and costimulatory
molecules in both c-DCs and CXCL12-DCs, their immunogenic
function may be different.
CXCL12 is expressed by perivascular macrophages in
tumor tissues
CXCL12 is involved in multiple aspects of tumor progression
including the trafficking and metastasis of malignant cells to organs
that express high levels of this chemokine, such as lymph nodes,
lungs, liver, and bone.25 Furthermore, CXCL12 can be synthesized
by tumor cells, fibroblasts, or perycytes within tumor tissues,3
where it may initiate the recruitment of blood monocytes to become
cancer-supporting macrophages in a CXCL12-rich microenviron-
ment. Thus, we examined metastatic melanoma samples that are
Figure 3. Effect of CXCL12 on monocyte-DCs differentiation and maturation
and immunogenic function. (A) PBMos were treated with GM-CSF and IL-4, in the
presence of CXCL12 (100 ng/mL) for 3 days. The expression of CD14 and CD1a was
analyzed by flow cytometry. Fold regulation relative to control untreated cells are
shown. Mean 	 SD; n  5; *P 
 .05. (B) PBMos were derived to DCs with GM-CSF
and IL-4, in the presence of CXCL12 (100 ng/mL), during the differentiation process.
Inmature DCs or LPS-matured DCs were stained with a panel of mAb as indicated.
The regions of positive cells were selected using the matched isotype control for each
mAb. A representative experiment out of 10 is presented. MFI of positive cells is
shown (C) CFSE-labeled autologous T lymphocytes were cocultured with unloaded,
PPD- or TT-loaded c-DCs and CXCL12-DCs, at 1:10 DC:T ratio. After 6 days,
lymphocytes were harvested, and the percentages of proliferating T cells (CFSElow)
were calculated. CXCL12-DCs induced lower CD4 T lymphocyte proliferation than
c-DCs, both in PPD- and TT-specific responses, as shown in 2 representative donors
(D#1 and D#2), from 4 individual donors with similar results. Unpulsed c-DCs and
CXCL12-DCs served as controls. The frequency of CD4 T cells in each
CFSE-dilution peak for PPD-specific proliferative responses of D#1 is shown in the
right panels.
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frequently infiltrated by tumor-associated macrophages (TAMs) to
analyze their phenotype. Human melanoma tissues were stained
with a panel of antibodies that recognize the major cell subsets:
melanocytic tumor cells (HMB45), macrophages (CD68, CD163,
and CD209), all leukocytes (CD45), mesenchymal cells (CD90
and -smooth muscle actin [-SMA]), and endothelial cells
(VE-cadherin, factor VIII; Figure 4, supplemental Figure 3, and
data not shown). The coexpression of CXCL12 with the different
cell subset panel Abs was analyzed by multicolor confocal
microscopy in 6 metastatic melanoma samples. Elevated levels of
CXCL12 were detected in stromal areas within the tumors and
associated with VE-cadherin blood vessels, but not within
HMB45 tumor cells (Figure 4A-B). Interestingly, in all the
samples studied there were 2 main subsets of highly expressing
CXCL12 (CXCL12high) cells; one subset colocalized with CD90
SMA myofibroblasts, and a second CXCL12high cell subset did
not colocalize with fibroblast markers (Figure 4A-B and data not
shown). A thoroughly immunofluorescence phenotyping showed
that this second subset of CXCL12high cells coexpressed the
macrophage antigens CD68, CD163, and CD209 and were often
accumulated in the vicinity of vascular structures (Figure 4C-E and
data not shown). These CXCL12high cells constituted the 60%-90%
of CD163 TAMs (Figure 4D) and were the predominant subset
found in tumor tissues (84.6 	 7.7 CD163/CD68). As shown in
Figure 4F, CD163 TAMs did not coexpress Tie-2, which was
expressed by endothelial cells (identified by costaining with Factor
VIII), suggesting that CD163 TAMs were distinct from the minor
subpopulation of highly proangiogenic monocytes that express
Tie-2.3 In contrast, in normal human skin, dermal macrophages
(CD68CD163CD209) were not accumulated at blood vessels
and displayed low costaining with CXCL12, which was highly
expressed by the basal layer of keratinocytes (supplemental Figure
3). We also analyzed the expression of CXCR4 and CXCR7
receptors by melanoma tissues. As we previously described, most
melanoma tumor cells highly express CXCR4,26,27 which was also
coexpressed by CXCL12highCD163 TAMs (Figure 4G). In con-
trast to the wide CXCR4 expression found in melanoma tissues,
CXCR7 was restricted to endothelial cells, and most intratumoral
CXCL12highCD163 TAMs barely expressed this receptor (supple-
mental Figure 3B-C). These data indicate that CXCL12/CXCR4
autocrine loop may play a primary role in the modulation of
macrophage differentiation at tumor tissues, whereas CXCR7
appears to be down-regulated in TAMs. Furthermore, these results
also reveal that TAMs comprise an important source of perivascu-
lar CXCL12 that could serve as a guidance clue for the recruitment
of either blood leukocytes or CXCR4 tumor cells at perivas-
cular sites.
CXCL12 induces the expression of CCL1 and VEGF
Perivascular CXCL12high expressing cells may ensure the ongoing
recruitment of monocytes into tumors, which are then entrapped
Figure 4. Most CXCL12 cells in metastatic melanoma tissues are
CD209 and CD163 tumor-associated macrophages that display a
perivascular location and express CXCR4. Metastatic melanoma
tissues were stained with anti-CXCL12 and the following tissue markers:
(A) melanocytic cells (HMb45) and myofibroblasts (CD90); (B) endothelial
cells (VE-cadherin, VE) and myofibroblasts (CD90); (C) macrophages
(CD209) and melanocytic cells (HMb45); and (D) quantification of
CXCL12 expression in macrophages CD163 was given as percentage.
Several melanoma metastases were analyzed: #45 lung metastasis;
#73, 79, 82, and 138 lymph node metastasis; and #98 skin metastasis.
(E) Macrophages (CD163). (F) Macrophages (CD163), endothelial cells
(Factor VIII), and TIE-2 positive cells. (G) Macrophages (CD163) and
CXCR4 cells (tumor and macrophages).
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and subverted by exposition to local high levels of CXCL12.
Therefore, the early transcriptional events associated with mono-
cyte exposition to CXCL12 were investigated. Resting human
monocytes from 3 separate donors were treated with either
CXCL12 or media alone, for 6 hours on Teflon dishes to minimize
the effect of adhesion. Microarray analysis was performed using
the ratios of the log2-transformed intensity values for each probe.
We focused our attention on the expression of macrophage
differentiation genes that characterize the M1-M2 (or classic
alternative) activation model.1,4 As shown in Figure 5A, CXCL12
stimulation did not significantly modify the mRNA expression of a
panel of prototypic M1 genes. CXCL12 had no effect on most
M2 genes either, including IL-10 mRNA and protein secretion
(Figure 5A-B). Interestingly, among the panel of M2 genes, we
identified the up-regulation of the chemokine CCL1 and the
endothelial growth factor VEGF, which are proangiogenic factors
that characterize a distinct pathway of M2 polarization.4 We
confirmed that primary monocytes cultured in the presence of
CXCL12 for 48 hours significantly augmented VEGF secre-
tion, and this increase was blocked by the CXCR4 antagonist
AMD3100 (Figure 5B). CCL1 mRNA expression was further
confirmed by real-time reverse transcription PCR analysis that
revealed a time-dependent induction in response to CXCL12
treatment (Figure 5C). Besides, an enhanced pool of intracellular
CCL1 protein was detected by flow cytometry in monocytes
exposed to CXCL12 (Figure 5D). These results indicate that the
important angiogenic factor VEGF and the proangiogenic chemo-
kine CCL1 are selectively up-regulated in response to CXCL12 in
human monocytes.
CXCL12 modulates the transcription factor RUNX3 in
primary monocytes
To assess the transcriptional basis of CXCL12-induced monocyte
differentiation, we decided to focus on the RUNX family of
transcription factors because it has been reported that RUNX3
mediates the TGF- responses in DCs.17 In addition, the expression
of PU.1 (Sp1), which controls monocyte development and differen-
tiation, is regulated by RUNX1.28 We found that RUNX1 and
RUNX2 transcription did not change upon CXCL12 treatment,
whereas RUNX3 and TGF- receptor appeared to be down-
regulated in the microarray data and in the qualitative PCR (Figure
6A and supplemental Figure 4A). qPCR showed that CXCL12
induced a significant down-regulation of RUNX3 mRNA expres-
sion both in primary monocytes and in THP-1 cells (Figure 6B and
supplemental Figure 4B). Remarkably, treatment of PBMos or
THP-1 cells with the CXCR4 antagonist AMD3100 induced
RUNX3 expression, indicating that the inhibition of the autocrine/
paracine CXCR4-CXCL12 axis was releasing the expression of
RUNX3 (Figure 6B and supplemental Figure 4B). A lesser effect in
RUNX3 expression was observed by blocking the CXCR7-
CXCL12 interaction with the CCX733 antagonist at this early time
point (6 hours) in PBMos and THP-1 cells (Figure 6B and
supplemental Figure 4B). These results demonstrate that interac-
tion of CXCL12 with CXCR4 is necessary and sufficient to repress
early RUNX3 transcription in blood monocytes, and therefore,
CXCL12 may down-regulate RUNX3-mediated TGF- signaling
in mononuclear cells.
Next, we analyzed the regulation of RUNX3 protein levels by
flow cytometry during the differentiation of PBMos to either
macrophages or DCs in the presence or absence of CXCL12.
Figure 6C shows the relatively low RUNX3 expression in PBMos
compared with the high RUNX3 expression that occurs during both
macrophage and DC differentiation (day 5). Moreover, the pres-
ence of CXCL12 during the differentiation process down-regulated
RUNX3 protein expression in both macrophages and DCs (day
5; Figure 6D). In addition, we analyzed the effect of CXCL12 on
the expression of RUNX3 by PBMos in several kinetics experi-
ments using 24-hour intervals, which showed a significant decrease
in RUNX3 protein levels at 72 hours in PBMos treated with
CXCL12 compared with unstimulated cells (Figure 6E). The
down-regulatory effect of CXCL12 treatment in RUNX3 expres-
sion was also detected by Western blot in M-CSF treated mono-
cytes (day 2) and THP-1 cells (Figure 6F and supplemental Figure
4C). Similarly to the effect of exogenous CXCL12, its autocrine
secretion (see Figure 2), may contribute to maintain a reduced basal
level of RUNX3 expression in PBMos and THP-1 cells. As
expected, treatment with CXCR4 or CXCR7 antagonists enhanced
RUNX3 protein expression, whereas addition of exogenous
CXCL12 (100 ng/mL) diminished RUNX3 protein levels in CXCR4
or CXCR7 antagonist-treated cells via the alternative receptor that
remained functional (Figure 6G and supplemental Figure
4D). RUNX3 protein changes in response to CXCL12 or CXCR4
or CXCR7 antagonists were also detected by flow cytometry in the
HSB-2 T lymphocytes, which expressed high basal levels of
RUNX3 (supplemental Figure 4E). Taken together, these results
indicate that CXCL12 down-regulates RUNX3 expression at
transcriptional and protein levels in blood monocytes and slows
down the up-regulation of RUNX3 that occurs during the initial
phases of macrophage and DC differentiation.
CXCL12-mediated RUNX3 down-regulation maintains the
expression of CD4 and CD14 in monocytes
We showed above that M-CSF–derived macrophages in the
presence of high doses of CXCL12 maintained higher surface
Figure 5. CXCL12 induces the proangiogenic factors VEGF and CCL1. (A) mRNA
extracted from PBMos stimulated with CXCL12 (100 ng/mL) or unstimulated (control)
was analyzed by microarrays. The ratios of the log2 intensity data of CXCL12-treated
cells versus Control for some M1 (top histogram) and M2 (bottom histogram) genes
are shown. Mean 	 SD; n  3. (B) ELISA quantification of secreted VEGF (black
filled histogram) and IL-10 (gray histogram) from peripheral blood monocytes
cultured for 48 hours. Cells were treated with AMD3100 and/or CCX733 as described
in Figure 2D. Mean 	 SE; n  3; *P 
 .05. (C) Time course of CCL1 mRNA
expression (qPCR) from PBMos stimulated with CXCL12 (100 ng/mL). Results were
normalized to GAPDH levels. Fold regulation relative to control untreated cells is
represented. Mean 	 SD; n  3. (D) Flow cytometric analysis of intracellular CCL1
protein expression in freshly isolated PBMos cultured for 12 hours (control, shaded
profile) compared with CXCL12-stimulated PBMos (black line). Control isotype
(discontinuous line). A representative experiment of 3 is shown.
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expression of CD4 compared with control macrophages (Figure
2E). RUNX3 silences the expression of CD4 in CD8 T cells
(recently reviewed29). As CXCL12 inhibited RUNX3 expression,
we next addressed its ability to regulate CD4 expression on blood
monocytes. To assess the effect of basal autocrine CXCL12
secretion on CD4 expression, blood monocytes were pretreated
with CXCR4 or CXCR7 antagonists and cultured for 48 hours.
CCX733 pretreatment significantly decreased the percentage and
the fluorescence intensity of CD4 monocytes (Figure 7A). We
next assessed if RUNX3 depletion by siRNA in THP-1 cells could
reproduce some of the CXCL12 effects reported above (Figure 2).
As expected, enhanced CD4 expression was detected in cells with
reduced levels of RUNX3 expression compared with control
siRNA (Figure 7B and supplemental Figure 4F). Interestingly,
CD14, the most important endotoxin receptor on human mono-
cytes,30 was also significantly augmented by RUNX3 depletion,
thus, phenocopying the effects of CXCL12 on CD4 and
CD14 expression. The lack of CD163 and CD209 expression on
THP-1 cells limited the analysis of the effect of RUNX3 depletion
on these molecules (data not shown). These results suggest that
CXCL12 maintains the long-term CD4 and CD14 expression in
monocytes through RUNX3 down-regulation.
Discussion
CXCL12 plays a critical role in monocyte extravasation and is
highly expressed at sites where macrophages are present in either
physiologic or pathologic situations.31 This study focuses on the
role of CXCL12 in shaping the process of monocyte differentiation
toward a distinct pathway characterized by proangiogenic and
immunosuppressive functions. Our results indicate that in addition
to regulate cell migration through both CXCR4 and CXCR7
receptors; CXCL12 enhances the expression of pathogen recogni-
tion receptors CD14 and CD163 and induces the secretion of
angiogenic factors as VEGF and CCL1. More importantly, the
presence of CXCL12 during the differentiation of monocytes to
DCs dampers their ability to induce antigen-specific activation of
T lymphocytes. Tumors are rich CXCL12 microenvironments, and
here we show that CXCL12 is highly expressed by perivascular
TAMs within melanoma tissues, supporting an autocrine/paracrine
positive feedback loop in the recruitment and differentiation of a
subset of monocytes with proangiogenic and immunosuppressive
functions, which may promote tumor progression. We provide data
indicating that CXCL12 may modulate gene expression and control
monocyte differentiation through down-regulation of the transcrip-
tion factor RUNX3.
Among the multiple processes in which CXCL12 and its
cognate receptors, CXCR4 and CXCR7, play a crucial role are the
development of embryonic vessels and tumor angiogenesis.6
Accumulating evidence demonstrates that CXCL12 has a major
role in the recruitment and retention of CXCR4 bone marrow–
derived cells to the neoangiogenic niches supporting revasculariza-
tion of ischemic tissue and tumor growth.31 However, the pheno-
types of proangiogenic bone marrow–derived cells and their
precise role in neovascularization are incompletely defined.
Stromal fibroblasts were previously identified as the major source
of CXCL12 in human breast carcinomas.24 In addition to fibro-
blasts, we have identified in metastatic melanoma a large and novel
subset of perivascular CXCL12high cells that coexpresses the
leukocyte marker CD45 and the macrophage markers CD68,
CD163, and CD209. The expression of CD209 has been described
on certain tissue macrophages, which are found in noninflamed
lymph nodes and at sites of inflammation, but not on DCs.32,33
Perivascular macrophages have been previously reported in other
types of human cancer and correlate with increased microvessel
Figure 6. CXCL12 modulates the transcription factor RUNX3. (A) mRNA
extracted from PBMos stimulated with CXCL12 (100 ng/mL) or unstimu-
lated (control) was analyzed by microarrays. CXCL12-induced regulation
of the expression of the RUNX family proteins and TGF- receptor was
compared. The ratios of the log2 intensity data of CXCL12-treated cells
versus Control for TGF-/RUNX selected genes are represented.
Mean 	 SD; n  3. (B) PBMos were incubated for 6 hours in the presence
() or absence () of CXCL12 (100 ng/mL), or the CXCR4 or CXCR7
antagonists AMD3100 (25 g/mL) and CCX733 (10nM), respectively.
RNA was extracted from cells and subjected to reverse transcriptase
reaction and qPCR for RUNX3 and normalized to GAPDH. Fold regulation
relative to control untreated cells is shown. Mean 	 SD; n  4; *P 
 .05.
(C) Runx3 expression was analyzed by flow cytometry on PBMos
(punctuated line), DCs (gray line), or macrophages (black line), by
stimulation for 5 days with GM-CSF plus IL-4 or M-CSF, respectively.
Control Isotype was also shown (shaded profile). A representative experi-
ment of 3 is shown. (D) PBMos were differentiated to DCs or macrophages
as described in panel C in the absence or presence of CXCL12 (100 ng/
mL), during the differentiation process. RUNX3 levels were analyzed by
flow cytometry. Fold regulation relative to control untreated () cells are
shown. Mean 	 SD; n  3; *P 
 .05. (E) PBMos were cultured in the
absence or in the presence of CXCL12 (100 ng/mL) during 5 days.
Percentages of RUNX3 positive cells were analyzed by flow cytometry at
the indicated times. Fold regulation relative to control untreated cells are
shown. Mean 	 SD; n  9; **P 
 .01. (F) PBMos induced with M-CSF
during 2 days were untreated () or treated with CXCL12 (100 ng/mL) as
indicated. Western blot of total lysates was performed. Results were
quantified by densitometry, normalized for differences in loading, and
expressed as fold increase compared with unstimulated controls. A
representative experiment out of 3 is shown. (G) PBMos were pretreated ()
with AMD3100 (25 g/mL) or CCX733 (10nM) or untreated () as control.
Subsequently, cells were stimulated with CXCL12 (100 ng/mL) as indicated.
Western blot of total lysates of 48 hours cultured cells was performed. Results
were quantified by densitometry, normalized for differences in loading, and
expressed as fold increase compared with unstimulated controls.A representa-
tive experiment of 3 is shown.
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density and poor prognosis.34 Perivascular CXCL12 expression has
been reported in a model of VEGF-induced adult neovasculariza-
tion, in which CXCL12 expression is downstream of VEGF and
contributes to the perivascular retention of myeloid cells that are
essential in the process.35 An important aspect of our work is the
proposal that perivascular CXCL12, in addition to participate in the
recruitment and retention of blood monocytes, drives a particular
pathway of macrophage differentiation, as suggested by the
CXCL12-induced up-regulation of important angiogenic factors as
VEGF and CCL1. Thus, VEGF appears to be both upstream and
downstream of CXCL12, suggesting the existence of a feedback
loop in the regulation of both factors. In addition, monocyte
recruitment and differentiation into CXCL12high expressing macro-
phages, which also coexpress CXCR4, may further increase the
tissue level of CXCL12 by an autocrine-paracrine loop, further
promoting the feedback mechanism for neovascularization associ-
ated to chronic inflammation. In fact, low oxygen tension, which is
a hallmark of inflammatory diseases and tumor microenvironment,
induces CXCR4 and CXCL12 expression through the hypoxia-
inducible factor-1.36,37 It has also been shown that hypoxia-
inducible factor-1, partly through increases in CXCL12, induces
recruitment of bone marrow–derived myeloid CD45 cells, which
provide MMP-9 to promote tumor angiogenesis.38 Identification of
the different cell populations and the mechanisms involved in
temporally and spatially supporting angiogenesis and/or vasculoge-
neis in specific types of tumors is currently under intense investiga-
tion to define specific treatment strategies. Interestingly, it has been
recently reported that the CXCR4 antagonist AMD3100 prevented
the influx of myelomonocytes and inhibited the development of
tumor vasculature resulting in abrogation of glioblastoma recur-
rence after irradiation in mice.39
In addition, we found that DCs derived in the presence of
CXCL12 are weaker stimulators of antigen-specific T-lymphocyte
responses. Mature DCs are traditionally considered to be immuno-
genic, although there is accumulating evidence that distinct states
of DC differentiation and maturation can also induce Ag-specific
regulatory T cells.40 Interestingly, it has been recently shown in a
mouse model of autoimmune disease that treatment with a CXCL12-
immunoglobulin fusion protein suppresses ongoing experimental
autoimmune encephalomyelitis, by selecting antigen-specific regu-
latory T cells.41 Recent findings support that CXCL12 functions as
an anti-inflammatory chemokine that may suppress the antigen-
specific immune responses.42
Our microarray analysis of CXCL12-treated monocytes re-
vealed that RUNX3, a transcription factor that regulates cell
lineage decisions in other cell systems, is down-regulated in the
presence of CXCL12. We show at transcriptional and protein levels
that the presence of CXCL12 slows down the RUNX3 up-
regulation that occurs during monocyte differentiation to either
macrophages or DC. Importantly, this is the first report of a
signaling pathway that regulates RUNX3 expression. The transcrip-
tion factor RUNX3 silences CD4 gene expression at the commit-
ment process into CD8 thymocytes.29 Human monocytes, macro-
phages, and DCs also express CD4, which is known to enhance
phagocytosis of apoptotic cells in CD4 macrophages.43 We show
that in monocytes, CXCL12 signaling is important for the mainte-
nance of both CD4 and CD14 expression through the repression of
RUNX3 transcription factor. CD14 is part of the lipopolysaccha-
ride “sensing apparatus” of monocytes and is also involved in
recognition and phagocytosis of apoptotic cells.30,44 Thus, CXCL12
effect on CD4 and CD14 levels seems to promote the scavenger
function of macrophages. In line with our findings, blocking of
CXCL12 or CXCR4 with specific antibodies reduced the propor-
tion of CD4 and CD4CD8 thymocytes.45 Furthermore, we have
demonstrated that both CXCR4 and CXCR7 receptors are involved
in the signaling that inhibits RUNX3 expression at transcriptional
and protein levels. Our data also show that both receptors are
involved in the migratory response of blood monocytes to CXCL12.
These results are in line with recent works that propose that both
receptors form functional CXCR4/CXCR7 heterodimers and that
CXCR7 is involved in specific CXCL12-mediated signaling.13,14
In summary, we report that as a part of the transcriptional
program elicited by CXCL12, this chemokine down-regulates the
expression of the transcriptional factor RUNX3. Reduced levels of
RUNX3 in turn maintain the expression of CD4 and CD14 by
macrophages in the process of differentiation. Other molecules
up-regulated by CXCL12 are the proangiogenic factors VEGF and
CCL1 and the macrophage scavenger receptor CD163. Impor-
tantly, CXCL12 down-modulates the ability of DCs to induce
antigen-specific immune responses. Given that CXCL12 is consti-
tutively expressed at sites of macrophage differentiation, as lung or
lymph nodes, and is up-regulated during chronic inflammatory
processes and cancer, CXCL12 is well-suited to control ongoing
monocyte recruitment, tissue retention, and specialized monocytic
differentiation under either steady-state or pathologic conditions.
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